The weight loss industry generates an extremely large amount of revenue every year. Unfortunately, a large percentage of this revenue is generated from products that fail to live up to their claims. Because losing weight is so difficult …

Acomplia (Rimonabant / Zimulti) received a major boost in the U.K. on March 26th when the National Institute for Health and Clinical Excellence recommended that acomplia will be made available to obese and overweight patients through the National Health Service.

The …

While millions of obese people are excited at Acomplia’s potential in helping them reduce their weight, some researchers believe this novel drug could have a major role to play in helping smokers break the cigarette habit — even though

…

On April 3rd Sanofi-Aventis published that it still has high hopes for Rimonabant (Acomplia / Zimulti) to get aproval from the FDA in US, even though it was rejected by an advisory panel last year and recent clinical trial …

Acomplia, generic name rimonabant, suffered a new setback on March 4th when the social court in Berlin-Brandenburg upheld a previous court ruling that German patients taking Sanofi-Aventis’s diet drug will not be reimbursed by their health insurers.

While Acomplia …